Comparative Pharmacology
Head-to-head clinical analysis: LEVOFLOXACIN IN DEXTROSE 5 IN PLASTIC CONTAINER versus MOXATAG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOFLOXACIN IN DEXTROSE 5 IN PLASTIC CONTAINER versus MOXATAG.
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER vs MOXATAG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby inhibiting DNA replication and transcription.
Amoxicillin (extended-release) inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin inhibitors, leading to cell lysis and death via activation of autolytic enzymes.
500 mg or 750 mg intravenously once daily. Infusion over 60-90 minutes.
775 mg orally once daily for 7 days.
None Documented
None Documented
6-8 hours in patients with normal renal function (creatinine clearance >50 mL/min); increases to 20-48 hours in severe renal impairment (CrCl <20 mL/min); clinically relevant for dosing interval adjustment.
The terminal elimination half-life is 1.0–1.5 hours in healthy adults; however, with the extended-release formulation (Moxatag), the effective half-life is prolonged to support once-daily dosing.
Renal: ~87% of dose excreted unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: <5% eliminated as unchanged drug and metabolites; <4% recovered in feces.
Approximately 60% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion; about 20% is excreted in feces via biliary elimination.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic